Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Robert Flisiak, Dorota Zarębska‐Michaluk, Magdalena Rogalska, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1279-1285
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Recent review of COVID-19 management: diagnosis, treatment and vaccination
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1120-1148
Open Access | Times Cited: 55
Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
Robert Flisiak, Piotr Rzymski, Dorota Zarębska‐Michaluk, et al.
Viruses (2023) Vol. 15, Iss. 1, pp. 149-149
Open Access | Times Cited: 38
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Differences between the course of SARS-CoV-2 infections in the periods of the Delta and Omicron variants dominance in Poland
Krystyna Dobrowolska, Michał Brzdęk, Dorota Zarębska‐Michaluk, et al.
Polskie Archiwum Medycyny Wewnętrznej (2023)
Open Access | Times Cited: 22
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Fangyuan Tian, Qiyi Feng, Zhaoyan Chen
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106870-106870
Open Access | Times Cited: 22
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1502-1502
Open Access | Times Cited: 19
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Jakob J Malin, Stephanie Weibel, Henning Gruell, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1586-1598
Open Access | Times Cited: 18
Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin
Antibiotics (2023) Vol. 12, Iss. 2, pp. 393-393
Open Access | Times Cited: 17
Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
Robert Flisiak, Dorota Zarębska‐Michaluk, Krystyna Dobrowolska, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5572-5572
Open Access | Times Cited: 17
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
Vivek P. Chavda, Divya Teli, Pankti C. Balar, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2332-2332
Open Access | Times Cited: 13
Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
Karima Benaicha, Raja Ram Khenhrani, Maha Veer, et al.
Cureus (2023)
Open Access | Times Cited: 13
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Ya‐Wen Tsai, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 13
Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
Christina Van Heer, S. S. Majumdar, Indra Parta, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 41, pp. 100917-100917
Open Access | Times Cited: 12
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1449-1449
Open Access | Times Cited: 11
Antiviral drugs against SARS-CoV-2
Tommaso Francesco Aiello, Carolina García‐Vidal, Álex Soriano
Revista Española de Quimioterapia (2022) Vol. 35, Iss. Suppl3, pp. 10-15
Open Access | Times Cited: 13
Molnupiravir is effective in patients with haematological malignancies
Łukasz Bołkuń, Bartosz Puła, Agnieszka Kołkowska‐Leśniak, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 6, pp. 1251-1256
Closed Access | Times Cited: 7
Inhibitors of the Structural and Nonstructural Proteins of Alphaviruses
Damilohun Samuel Metibemu, Olawale Samuel Adeyinka, John Adeolu Falode, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 8, pp. 2507-2524
Closed Access | Times Cited: 2
Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
Krystyna Dobrowolska, Dorota Zarębska‐Michaluk, Michał Brzdęk, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2371-2371
Open Access | Times Cited: 6
Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
Kinga Czarnecka, Paulina Czarnecka, Olga Tronina, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6464-6464
Open Access | Times Cited: 8
Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Behnam Amani
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 1
Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
Ivana Gmizić, Aleksandra Barać, Nevena Todorović, et al.
The Journal of Infection in Developing Countries (2024) Vol. 18, Iss. 05, pp. 694-700
Open Access | Times Cited: 1
Vaccination options for pregnant women during the Omicron period
Jiarui He, Zichun Wei, Taiyang Leng, et al.
Journal of Reproductive Immunology (2023) Vol. 156, pp. 103798-103798
Open Access | Times Cited: 3
Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Kohei Fujita, Osamu Kanai, Hiroaki Hata, et al.
Aging and Health Research (2023) Vol. 3, Iss. 2, pp. 100130-100130
Open Access | Times Cited: 3
Differences in Clinical Presentation of COVID-19 in Children Hospitalized During Domination of Early (BA.1, BA.2) and Late (BA.5, BA.2.75, BQ.1 and XBB.1.5) SARS-CoV-2 Omicron Subvariants
Maria Pokorska‐Śpiewak, Małgorzata Pawłowska, Przemysław Ciechanowski, et al.
The Pediatric Infectious Disease Journal (2023) Vol. 43, Iss. 2, pp. 149-154
Open Access | Times Cited: 3
Early oral antiviral use in patients hospitalised with COVID-19
Dorota Zarębska‐Michaluk, Robert Flisiak
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1650-1651
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top